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Neutropenia encompasses a family of neutropenic disorders, both permanent and intermittent, ranging from severe
(<500 neutrophils/mm3) to mild (500–1500 neutrophils/mm3), which may also affect other organ systems such as
the pancreas, central nervous system, heart, muscle and skin. Neutropenia can lead to life-threatening pyogenic
infections whose severity is roughly inversely proportional to the circulating neutrophil counts.
When neutropenia is detected, an attempt should be made to establish the etiology, and to distinguish acquired
forms (the most frequent, including post viral neutropenia and autoimmune neutropenia) and congenital forms
(rare disorders) that may be either isolated or part of a complex rare genetic disease. We report on a male patient
initially diagnosed with isolated neutropenia who later turned out to be affected with Barth syndrome, a rare
complex inherited disorder.
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Neutropenia is a laboratory finding associated with vari-
able severity ranging from benign transient neutropenia,
such as that due to mild viral infection, to congenital
neutropenia (CN). The latter is generally characterized
by a bone marrow failure with developmental arrest of
myelopoiesis at the promyelocyte/myelocytic stage, lead-
ing to an absolute neutrophil count (ANC) in the per-
iphery below 500/mm3. Affected patients are particularly
prone to severe infections. Molecular and genetic ad-
vances in the field of CN has not only allowed a better
classification of this disorder, based on the underlying
genetic defect, but has also shed light on the molecular
mechanisms regulating both development and function
of neutrophils [1]. From the clinical point of view, two
major groups of CN can be distinguished: isolated CN
without associated organ involvement, and CN associ-
ated with syndromic features [1]. Thus, it is important* Correspondence: plebani@med.unibs.it
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carefully investigated for associated signs and symptoms
that may underlie a more complex and rare disorder.
We report on a patient initially diagnosed with isolated
neutropenia in whom a diagnosis of Barth syndrome
(BTHS) was achieved later in life after the identification
of cardiomyopathy (CMP) during an hospital admission
for a respiratory infection.Case report
The patient was born from an uneventful pregnancy
with normal perinatal conditions. The patient's mother
reported one previous miscarriage during the first weeks
of gestation. At birth, the patient's body measurements
were at the lower percentile: weight was 2.870 g (10th
percentile), length 49 cm (10th percentile) and head cir-
cumference 32 cm (<3rd percentile). No family history
of CMP was reported. The patient's clinical history in-
cluded a first admission at the age of 9 days for omphali-
tis. During this admission, borderline neutropenia was
found (ANC: 1010/mm3). He was discharged with indi-
cations to perform periodical controls of neutrophil
count. During these periodical controls, a severe neutro-
penia (WBC: 6140/mm3; ANC: 80/mm3) was detected atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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marrow aspirate showed a maturational arrest of neutro-
phil precursors at the promyelocytic stage. The routine
laboratory work up, including serology for viruses and
bacteria and anti-neutrophil-specific antibodies, was
negative. Genetic analysis of the ELANE and HAX1
genes, mutations which account for 60-70% of congeni-
tal neutropenia, did not reveal any alteration. Treatment
with Granulocyte-Colony Stimulating Factor (G-CSF)
(10 μg/kg/day) was undertaken due to severe neutro-
penia and withdrawn after stable normalization of ANC
(1600/mm3). The patient was discharged with diagnosis
of CN and was regularly followed at the outpatient
clinic.
The patient was admitted again at the age of 24 months
for febrile neutropenia (ANC: 400/mm3). His body mea-
surements were still at the lower percentile for age:
weight 10.4 Kg (3rd percentile) and height 82.5 cm (3rd
percentile). Analysis of the growth charts confirmed the
progressive growth delay. Auscultation revealed wheez-
ing and crackles; pulse oximetry was 96%. Cardiac exam-
ination was unremarkable with a heart rate of 125 beats/
minute and arterial pressure of 83/49 mmHg. Abdom-
inal evaluation revealed hepatomegaly. Chest radiog-
raphy ruled out pneumonia but revealed the presence of
cardiomegaly (Figure 1). Echocardiographic evaluation
documented dilated CMP, with marked enlargement of
the left ventricle and severe impairment of the systolicFigure 1 Chest X-ray showing severe cardiomegaly.function (left ventricular ejection fraction of 20%).
Nevertheless left ventricular wall and septal thickness
were preserved and myocardial trabeculature was un-
usually prominent, though not enough to fulfill the cri-
teria for the diagnosis of left ventricular noncompaction
(LVNC) [2] (Figure 2A and B). The pediatric cardiologist
prescribed treatment with Furosemide 1 mg/Kg intraven-
ously, Captopril 1 mg/kg and Spironolactone 2.5 mg/kg.
No syndromic clinical features were evident and neuro-
logic examination was unremarkable.
After reviewing the patient's features (neutropenia,
growth delay, and cardiomyopathy), BTHS was taken
into consideration. The presence of urine organic acids
(elevated levels of urinary 3-methylglutaconic acid)
strongly supported this diagnostic hypothesis. Genetic
analysis of the tafazzin gene (TAZ), the causative gene of
BTHS, revealed a c646 G > A substitution, leading to the
aminoacidic substitution p.Gly216Arg, confirming there-
fore the diagnosis of BTHS. The patient was discharged
in stable condition with the following maintainance ther-
apy: Furosemide 0.5 mg/kg, Carvedilol 0.2 mg/kg, Enalapril
0.25 mg/kg and Aldactazide 1.5 mg/kg, with good cardio-
logical control until the last outpatient visit. He was put on
G-CSF treatment 3 μg/Kg three times a week, a dose which
allowed to maintain ANC between 1500-2000/mm3.
Discussion
Barth syndrome is a rare X-linked disorder caused by
mutations in the TAZ gene, also named G4-5 gene, en-
coding for the tafazzin protein. This protein is a
phospholipid transacylase which is located in the inner
leaflet of the mitochondrial membrane and plays an im-
portant role in the remodeling of cardiolipin which is
known to be critical in maintaining mitochondrial struc-
ture as well as being involved in mitochondrial apoptosis
[3,4]. BTHS is the first known inborn error that affects
cardiolipin. Although the classical clinical phenotype is
characterized by CMP, often with LVNC morphology,
neutropenia, skeletal myopathy, growth delay, and typ-
ical facial features, the presence of these findings can
vary significantly, likely resulting in underdiagnosis of
this disorder [3-5]. Furthermore, male fetal loss, stillbirth
and severe neonatal illness or death have been found in
multiple families with BTHS [6].
The molecular mechanisms leading to the variable
expression of these clinical features are still largely
unknown.
CMP is the major clinical feature in BTHS, with high
prevalence in early life, which can present with different
cardiac phenotypes [3,4,7,8]. LVNC is also commonly
seen either alone or in conjunction with other CMP
phenotypes and is characterized by trabeculations in left
ventricle with associated wall motion abnormalities [9].
In our patient the atypical appearance of the apex and
Figure 2 Echocardiographic images of the index patient. Both in apical four chamber (A) and in parasternal long axis view (B). The left
ventricle (LV) appears dilated and spherical in shape. Note the preserved thickness of the parietal and septal myocardium with the relative
prominence of the trabeculae of the apex and lateral wall (arrows).
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diagnostic criteria for LVNC were not entirely fulfilled
[2]. About 70% of BTHS patients are recognized to have
CMP in the first year and all those who developed CMP
do so by 5 years of age [7]. However, a diagnostic delay
for BTHS in patients with CMP has been reported. Data
from Pediatric Cardiomyopathy registries of the USA
suggest that 3-5% of all boys with CMP have BTHS [3].
Initial presentation of BTHS-associated CMP may
mimic viral myocarditis or may become clinically evi-
dent during viral infections. BTHS should therefore al-
ways be included in the differential diagnosis of males
presenting with CMP of apparent viral infection, espe-
cially when neutropenia is present (which could be as-
cribed to secondary bone marrow suppression by viral
infection).
Neutropenia is very common in BTHS and may be
persistent or intermittent [3]. However, there may be a
wide variability of the neutrophil counts with some pa-
tients having extremely low levels of neutrophils and
others having from mild decrease to normal levels of cir-
culating neutrophils [7]. Therefore, the decision to
undertake treatment with G-CSF is largely dependent on
the patient’s clinical features and ANC [3]. Neutropenia
may be the initial finding in an undiagnosed BTHS pa-
tient. Growth delay is another well-described clinical fea-
ture of BTHS [1,3,7,8].
In our patient, neutropenia, from mild to severe, was
the first symptom of presentation early in life, of what
was later diagnosed as BTHS. During follow up, apart
from neutropenia, the only additional clinical finding
was a persistent growth delay. Cardiomyopathy, appar-
ently in the absence of clinical symptoms, was detected
incidentally during an hospital admission at the age of
24 months. No other clinical features such as motor
delay or skeletal myopathy became apparent by this age,
thus, a clinical diagnosis was not made until the patient
was diagnosed with dilated cardiomyopathy. However,
an early diagnosis could have been suspected by linkingchronic neutropenia to growth delay starting from the
perinatal period.
In our case the finding of raised urinary levels of 3-
methylglutaconic acid strongly supported BTHS diag-
nosis. However it is well known that this parameter is a
rather non-specific indicator of the disease since cases
have been reported where urinary 3-methylglutaconic
acid levels have been normal in patients with TAZ mu-
tations [3]. Recently a new method based on the CL4
and MLCL/CL4 (monolysocardiolipin/tetralinoleyl car-
diolipin) analysis, has been proposed as a suitable
highly sensitive diagnostic test for BTHS [10].
Previously, BTHS was often considered as a lethal dis-
ease during infancy and early childhood.
However, improvements in management of associated
neutropenia and cardiac disease have resulted in better
survival. Although mortality remains high during the
first 4 years of life, patients are reported to survive into
their late 40s [3,11] in response to improvements of sup-
portive therapy. Thus clinicians should consider BTHS
early in the course of the clinical evaluation of males
with persistent idiopathic neutropenia since an early rec-
ognition of abnormal signs and symptoms associated
with BTHS is crucial to improve the clinical outcome of
the affected patients. Furthermore, genetic diagnosis of
BTHS allows for a correct genetic counselling.
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